MX2020008704A - Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro. - Google Patents

Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro.

Info

Publication number
MX2020008704A
MX2020008704A MX2020008704A MX2020008704A MX2020008704A MX 2020008704 A MX2020008704 A MX 2020008704A MX 2020008704 A MX2020008704 A MX 2020008704A MX 2020008704 A MX2020008704 A MX 2020008704A MX 2020008704 A MX2020008704 A MX 2020008704A
Authority
MX
Mexico
Prior art keywords
bupropion
dosage forms
enantiomerically enriched
methods
pure bupropion
Prior art date
Application number
MX2020008704A
Other languages
English (en)
Spanish (es)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of MX2020008704A publication Critical patent/MX2020008704A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020008704A 2018-02-23 2019-02-25 Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro. MX2020008704A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US201962809480P 2019-02-22 2019-02-22
PCT/US2019/019445 WO2019165379A1 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Publications (1)

Publication Number Publication Date
MX2020008704A true MX2020008704A (es) 2020-12-07

Family

ID=67688503

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020008704A MX2020008704A (es) 2018-02-23 2019-02-25 Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro.
MX2023009281A MX2023009281A (es) 2018-02-23 2020-08-20 Formas y metodos de dosis para bupropion enantiomericamente enriquecido o puro.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023009281A MX2023009281A (es) 2018-02-23 2020-08-20 Formas y metodos de dosis para bupropion enantiomericamente enriquecido o puro.

Country Status (19)

Country Link
EP (1) EP3755312A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021513998A (cg-RX-API-DMAC7.html)
KR (3) KR20240091043A (cg-RX-API-DMAC7.html)
CN (2) CN112087999A (cg-RX-API-DMAC7.html)
AU (3) AU2019223187B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020017179A2 (cg-RX-API-DMAC7.html)
CA (1) CA3092076A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002166A1 (cg-RX-API-DMAC7.html)
CR (1) CR20200415A (cg-RX-API-DMAC7.html)
EC (1) ECSP20060179A (cg-RX-API-DMAC7.html)
IL (2) IL276871B2 (cg-RX-API-DMAC7.html)
MA (1) MA51914A (cg-RX-API-DMAC7.html)
MX (2) MX2020008704A (cg-RX-API-DMAC7.html)
MY (1) MY202993A (cg-RX-API-DMAC7.html)
NI (1) NI202000056A (cg-RX-API-DMAC7.html)
NZ (1) NZ767378A (cg-RX-API-DMAC7.html)
PE (1) PE20211752A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202008056SA (cg-RX-API-DMAC7.html)
WO (1) WO2019165379A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3092076A1 (en) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
CN114423417A (zh) * 2019-09-20 2022-04-29 艾克萨姆治疗公司 用于对映体富集的或纯的安非他酮的剂型和方法
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
KR20250114110A (ko) 2022-11-28 2025-07-28 안테씨프 바이오벤쳐스 투 엘엘씨 약물 활성의 조절제로서의 부프로피온
WO2025259728A1 (en) * 2024-06-13 2025-12-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038502A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
CN1819821B (zh) * 2003-08-08 2010-10-13 拜奥维尔实验室国际股份有限公司 盐酸安非他酮的改良释放片剂
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
EP3981403A1 (en) * 2013-11-05 2022-04-13 Antecip Bioventures II LLC Compositions and methods comprising bupropion or related compounds and dextromethorphan
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
MX2013014166A (es) * 2013-12-03 2015-06-10 Inst De Investigacion En Quimica Aplic S A De C V Enantiomeros activos y sus sales para el tratamiento de la obesidad.
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
CA3092076A1 (en) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion

Also Published As

Publication number Publication date
CA3092076A1 (en) 2019-08-29
PE20211752A1 (es) 2021-09-06
CN120827545A (zh) 2025-10-24
AU2019223187A1 (en) 2020-09-17
NI202000056A (es) 2021-01-11
IL276871A (en) 2020-10-29
JP2021513998A (ja) 2021-06-03
MY202993A (en) 2024-05-31
KR20240091043A (ko) 2024-06-21
IL276871B2 (en) 2024-11-01
AU2024205858A1 (en) 2024-09-05
IL313368A (en) 2024-08-01
WO2019165379A1 (en) 2019-08-29
ECSP20060179A (es) 2020-12-31
CN112087999A (zh) 2020-12-15
MX2023009281A (es) 2023-08-17
EP3755312A1 (en) 2020-12-30
BR112020017179A2 (pt) 2020-12-22
KR20230075531A (ko) 2023-05-31
AU2022204521A1 (en) 2022-07-21
CL2020002166A1 (es) 2020-10-23
AU2022204521B2 (en) 2024-09-05
NZ767378A (en) 2024-03-22
JP2024075655A (ja) 2024-06-04
AU2019223187B2 (en) 2022-07-28
CR20200415A (es) 2021-02-03
MA51914A (fr) 2020-12-30
SG11202008056SA (en) 2020-09-29
IL276871B1 (en) 2024-07-01
KR20210003091A (ko) 2021-01-11
EP3755312A4 (en) 2022-03-16
JP2022153638A (ja) 2022-10-12

Similar Documents

Publication Publication Date Title
NI202000056A (es) Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro
ES3063891T3 (en) Methods of reducing the risk of cardiovascular events in a subject
CL2021003306A1 (es) Agentes, usos y métodos para el tratamiento de la sinucleinopatía. (divisional de solicitud nº 201901293)
MX2020012966A (es) Combinacion, composicion y preparacion de combinacion farmaceutica que comprende activador de glucocinasa e inhibidor de sglt-2, metodos de preparacion y usos de las mismas.
SV2018005612A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia
MX2016010235A (es) Composicion farmaceutica que comprende eritrocitos que encapsulan una enzima dependiente de fosfato de piridoxal (plp) y su cofactor.
GT201600137A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
WO2020061486A3 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
AR116451A1 (es) Administración oral de análogos del péptido glp-1
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
BR112018074655A2 (pt) formulação injetável de fosnetupitant e método de fabricação de uma formulação
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
BR112018074434A2 (pt) composições farmacêuticas compreendendo safinamida
ECSP22030119A (es) Formas de dosificación y métodos para bupropión enantioméricamente enriquecido o puro
MX381450B (es) Un medicamento combinado que comprende fenilefrina y paracetamol
EP4631500A3 (en) STABLE MULTIPARTICULAR PHARMACEUTICAL COMPOSITION OF ROSUVASTATIN
MX2018010367A (es) Titulacion de cebranopadol.
MY203254A (en) Pharmaceutical preparation
MX2020004403A (es) Composiciones farmaceuticas que comprenden safinamida.
CO2017000354A2 (es) Desmopresina estabilizada
BR112021011755A8 (pt) Método para fornecer um benefício de tratamento bucal com o uso de um composto de cálcio de baixa solubilidade e fluoreto